Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
1(7%)
Results Posted
62%(8 trials)

Phase Distribution

Ph phase_1
6
43%
Ph phase_2
3
21%
Ph phase_3
4
29%

Phase Distribution

6

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
6(46.2%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
4(30.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(13)

Detailed Status

Completed13
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (46.2%)
Phase 23 (23.1%)
Phase 34 (30.8%)

Trials by Status

completed1393%
recruiting17%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT06061536Phase 2

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

Completed
NCT03547908Phase 3

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

Completed
NCT03639311Phase 2

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

Completed
NCT03564613

Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women

Recruiting
NCT04857892Phase 1

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

Completed
NCT02227238Phase 3

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

Completed
NCT02607956Phase 3

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT03110380Phase 3

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

Completed
NCT02397694Phase 2

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT03816696Phase 1

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

Completed
NCT02741557Phase 1

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

Completed
NCT01563328Phase 1

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Completed
NCT02082808Phase 1

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

Completed
NCT01967771Phase 1

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14